Curis has started dosing patients in a Phase l trial of CA-4948 to treat patients with lymphoma.

CA-4948 is an orally available small molecule inhibitor of IRAK4 kinase, and the second licensed programme from a partnership between Curis and Aurigene to enter the clinic.

The Phase l trial seeks to assess the safety, tolerability, and pharmacokinetic profile of CA-4948.

It also aims to identify any dose-limiting toxicities and establish the recommended Phase ll dose for treatment of patients with lymphomas.

“IRAK4 represents a significant target for the precision treatment of patients with different hematologic malignancies.”

The trial’s dose escalation stage will enrol patients with relapsed/refractory non-Hodgkin’s lymphoma, while the expansion stage will focus on specific populations of patients with lymphomas harbouring alterations in the MYD88 gene or toll-like receptor (TLR) signalling pathway.

Curis president and CEO Ali Fattaey said: “Given the prevalence of activating mutations in the MYD88 gene and the TLR pathway, IRAK4 represents a significant target for the precision treatment of patients with different hematologic malignancies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“In addition to its preclinical anti-tumor activity in MYD88-mutated lymphomas, we have observed encouraging effects of CA-4948 in animal models of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) as well as non-oncology inflammatory disease models.”

In addition, Curis has partnered with Aurigene to collaborate in the fields of immuno-oncology and precision oncology.